Implant Sciences to Exhibit Quantum Sniffer at the ASIS International 50th Annual Seminar & Exhibits
"Quantum Sniffer" will be exhibited at the ASIS International 50th Annual Seminar & Exhibits
(PRWEB) September 27, 2004 -- Implant Sciences Corporation (AMEX: "IMX",
"IMX.WS") a developer and manufacturer of products for national security,
medicine and industry, today announced that its "Quantum Sniffer" will be
exhibited at the ASIS International 50th Annual Seminar & Exhibits. The
American Society of Industrial Security (ASIS), the world's most comprehensive
educational and networking event in the security industry is meeting at the
Dallas Convention Center. The Seminar is specifically designed for and by
security professionals, and runs from September 27th through September 29th.
Senior management and sales represenatative personnel from Implant Sciences will
be located at booth 6009 on the exhibit floor.
The Quantum Sniffer is the
Company's trace explosives detection device using the Company's proprietary QSTM
Ion Mobility Spectrometry technology, which electronically detects minute
quantities of explosive vapor molecules in the air. These units may be used to
determine the presence of, or confirm the absence of, common explosives in
personal equipment, packages, postal mail and cargo that may be conveyed by
persons, vehicles, airplanes, and watercraft.
Dr. Anthony J. Armini,
Chairman and CEO of Implant Sciences commented, “After many years of research
and development, we are excited about the opportunity to unveil our production
ready version of the Quantum Sniffer at this important exhibit for security
professionals. The equipment to be exhibited includes devices that will soon be
submitted to the US Navy and the TSA in accordance with the terms of currently
existing contracts with these agencies. We look forward to a successful
presentation of our new products for the security industry and look forward to
the future prospects that our Quantum Sniffer holds for Implant Sciences
Corporation.”
Dr. Anthony J. Armini, further stated, “I would like to
thank each and every member of Implant Sciences for their hard work in every
aspect of the process of bringing this product from a vision to a reality. And I
would especially like to extend my gratitude to all of the shareholders,
investors and business partners who have contributed their resources and money,
and most importantly, their loyalty to the goal of making Implant Sciences a
successful company. We hope that as a result of these many contributions, lives
will be saved domestically and internationally.”
About Implant
Sciences
Implant Sciences, incorporated in 1984, is using its core ion
technology to develop, manufacture and market products for national security,
medicine, and industry. Under development are portable and bench-top trace
element detection devices to identify explosives, narcotics and other toxic
materials. The Company has also received government grants from the US Army,
Navy and Air Force, and the Transportation Security Administration to adapt the
Company's explosive detection technology to a wide number of security
requirements.
Using its proprietary ion implantation and thin film
coating technologies, Implant Sciences has a sophisticated production line that
modifies the surface characteristics of orthopedic joint implants to reduce
polyethylene wear, thereby substantially increasing the life of the implants.
The company also manufactures and markets radioactive and non-radioactive
products for medical use, including radioactive seeds for treating prostate
cancer that are distributed throughout the United States by its own direct sales
force. In parallel with the production of these seeds, it is also developing
additional brachytherapy products for the treatment of breast, eye, and other
cancers.
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words "believe",
"estimate", "project", "expect" or similar expressions. These statements are
made pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially from the
forward-looking statements. Factors that would cause or contribute to such
differences include, but are not limited to, continued acceptance of the
Company's products and services in the marketplace, the ability of the Company
to develop effective new products and receive governmental approvals of such
products, competitive factors, dependence upon third-party vendors, and other
risks detailed in the Company's periodic report filings with the Securities and
Exchange Commission. By making these forward-looking statements, the Company
undertakes no obligation to update these statements for revisions or changes
after the date of this release.
# # #
Source : http://www.prweb.com/releases/2004/9/prweb161482.htm